Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Alphabet Director Frances Arnold Sells $28.3K of Stock
Frances Arnold, Director, sold 83 shares of Alphabet Inc. at $340.45 a share, worth $28.3K in total on Sep 30, 2026. Shares held after the trade: 19,076 (-0.4%).
PennyMac Mortgage Investment Trust CAO Gregory L. Hendry Sells $19.2K of Stock
Gregory L. Hendry, CAO, sold 2,444 shares of PennyMac Mortgage Investment Trust at $7.86 a share, worth $19.2K in total on Oct 1, 2026. Shares held after the trade: 4,886 (-33.3%).
Roblox Insider Gregory Baszucki Sells $714K of Stock
Gregory Baszucki sold 16,666 shares of Roblox Corp at $42.57 to $43.03 a share (average $42.87) in 4 transactions, worth $714K in total on Oct 1, 2026. Shares held after the trade: 1,252,836 (-0.4%).
Mineralys Therapeutics CEO Jon Congleton Sells $1.91M of Stock
Jon Congleton, CEO, sold 75,000 shares of Mineralys Therapeutics, Inc. at $25.46 a share, worth $1.91M in total on Sep 30, 2026. Shares held after the trade: 528,621 (-12.4%).
Rivian Automotive Chief Administrative Officer Michael John Callahan Sells $225K of Stock
Michael John Callahan, Chief Administrative Officer, sold 15,000 shares of Rivian Automotive, Inc. at $15.00 a share, worth $225K in total on Oct 1, 2026. Shares held after the trade: 1,001,776 (-1.5%).
Oric Pharmaceuticals Director Richard A. Heyman Sells $86.5K of Stock
Richard A. Heyman, Director, sold 6,700 shares of Oric Pharmaceuticals, Inc. at $12.91 a share, worth $86.5K in total on Oct 1, 2026. Shares held after the trade: 203,472 (-1.5%).
Rubrik Director John Wendell Thompson Sells $1.56M of Stock
John Wendell Thompson, Director, sold 13,500 shares of Rubrik, Inc. at $114.68 to $116.47 a share (average $115.69) in 6 transactions, worth $1.56M in total on Oct 1, 2026. Shares held after the trade: 8,362 (-22.3%).
Cactus Chairman and CEO Scott Bender Sells $6.2M of Stock
Scott Bender, Chairman and CEO, sold 100,000 shares of Cactus, Inc. at $61.97 a share, worth $6.2M in total on Oct 1, 2026. Shares held after the trade: 120,527 (-45.3%).
Joel Bender, President, sold 100,000 shares of Cactus, Inc. at $61.97 a share, worth $6.2M in total on Oct 1, 2026. Shares held after the trade: 41,519 (-70.7%).
First Solar CTO Markus Gloeckler Sells $139K of Stock
Markus Gloeckler, CTO, sold 800 shares of First Solar, Inc. at $174.00 a share, worth $139K in total on Oct 1, 2026. Shares held after the trade: 5,042 (-13.7%).
Anaptysbio Director Hollings Renton Sells $249K of Stock
Hollings Renton, Director, sold 5,000 shares of Anaptysbio, Inc at $49.87 a share, worth $249K in total on Oct 1, 2026. Shares held after the trade: 10,995 (-31.3%).
CI&T Insider Fernando Matt Borges Martins Buys $13.1K of Stock
Fernando Matt Borges Martins bought 4,123 shares of CI&T Inc at $3.18 a share, worth $13.1K in total on Oct 1, 2026. Shares held after the trade: 4,123.
Roivant Sciences President & Immunovant CEO Eric Venker Sells $7.32M of Stock
Eric Venker, President & Immunovant CEO, sold 200,000 shares of Roivant Sciences Ltd. at $36.62 a share, worth $7.32M in total on Sep 30, 2026. Shares held after the trade: 1,599,154 (-11.1%).
Stoke Therapeutics General Counsel & Corp Sec Jonathan Allan Sells $16.5K of Stock
Jonathan Allan, General Counsel & Corp Sec, sold 627 shares of Stoke Therapeutics, Inc. at $26.33 a share, worth $16.5K in total on Oct 2, 2026. Shares held after the trade: 20,598 (-3.0%).
Stoke Therapeutics CMO Barry Ticho Sells $27.5K of Stock
Barry Ticho, CMO, sold 1,051 shares of Stoke Therapeutics, Inc. at $26.16 a share, worth $27.5K in total on Oct 1, 2026. Shares held after the trade: 19,059 (-5.2%).
Walmart EVP Daniel J. Bartlett Sells $417K of Stock
Daniel J. Bartlett, EVP, sold 3,990 shares of Walmart Inc. at $104.41 a share, worth $417K in total on Oct 1, 2026. Shares held after the trade: 618,359 (-0.6%).
Amit Gupta, CEO, sold 17,733 shares of Cardlytics, Inc. at $2.53 to $2.71 a share (average $2.64) in 2 transactions, worth $46.7K in total between Oct 1, 2026 and Oct 2, 2026. Shares held after the trade: 138,906 (-5.0%).
Outdoor Holding Company held its 2026 Annual Meeting of Stockholders on September 28, 2026, where shareholders approved the redomestication of the company from Delaware to Texas. The conversion became effective on September 30, 2026, resulting in the company's internal affairs being governed by Texas law and the automatic conversion of outstanding common and preferred shares into shares of the new Texas corporation.
ChronoScale Holdings Corporation completed the sale of its wholly owned subsidiary, Ekso Bionics, Inc., to focus resources on its core AI infrastructure business. In connection with the divestiture, Ekso's COO Jason C. Jones was terminated and received a severance package totaling approximately $0.24 million. The company also announced new AI infrastructure contracts expected to drive an annualized revenue run rate of $1 billion by Q3 2027.
Richtech Robotics Inc. held its 2026 Annual Meeting of Stockholders on September 29, 2026. Shareholders elected Saul Factor and John Shigley to the Board of Directors for three-year terms and ratified the appointment of CBIZ CPAs P.C. as the company's independent auditor.
KKR Enhanced US Direct Lending Fund-L Inc. declared a dividend of $10.05 per share on its common shares. The dividend is payable on or about October 30, 2026, to shareholders of record as of September 30, 2026.
Nurix Therapeutics CLO Christine Ring Sells $134K of Stock
Christine Ring, CLO, sold 5,786 shares of Nurix Therapeutics, Inc. at $23.19 a share, worth $134K in total on Oct 2, 2026. Shares held after the trade: 9,110 (-38.8%).
Tonix Pharmaceuticals received a Paragraph IV patent certification notice from Dr. Reddy’s Laboratories (DRL) regarding an Abbreviated New Drug Application (ANDA) for a generic version of TONMYA®. DRL claims that four of Tonix's Orange Book-listed patents are invalid, unenforceable, or not infringed. Tonix intends to vigorously enforce its intellectual property rights, which could trigger an automatic 30-month stay of FDA approval for the generic product.
Counterparty
Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories, Inc.
Healthcare Triangle received a Staff Delisting Determination from Nasdaq on October 1, 2026, for failing to maintain the $1.00 minimum bid price requirement. Because the company has already effected cumulative reverse stock splits exceeding a 1-for-250 ratio over the last two years, it is ineligible for a standard 180-day compliance period. The company intends to appeal the delisting determination to a Nasdaq Hearings Panel, which will stay the suspension of its common stock pending a decision.
PTC Therapeutics Director Glenn Steele Jr. Md. Phd. Sells $782K of Stock
Glenn Steele Jr. Md. Phd., Director, sold 12,000 shares of PTC Therapeutics, Inc. at $65.16 a share, worth $782K in total on Sep 30, 2026. Shares held after the trade: 22,500 (-34.8%).
Rocket Lab CFO Adam C. Spice Sells $9.93M of Stock
Adam C. Spice, CFO, sold 140,157 shares of Rocket Lab Corp at $70.28 to $71.79 a share (average $70.82) in 3 transactions, worth $9.93M in total on Oct 1, 2026. Shares held after the trade: 1,155,967 (-1.3%).
Raymond Woo, CTO, sold 4,887 shares of Ceribell, Inc. at $24.38 a share, worth $119K in total on Oct 1, 2026. Shares held after the trade: 203,118 (-2.3%).
Oramed Pharmaceuticals CFO Avraham Gabay Sells $90.2K of Stock
Avraham Gabay, CFO, sold 20,000 shares of Oramed Pharmaceuticals Inc. at $4.51 a share, worth $90.2K in total on Oct 1, 2026. Shares held after the trade: 861,076 (-2.3%).
Joshua Hexter, COO & Cbo, sold 30,000 shares of Oramed Pharmaceuticals Inc. at $4.51 a share, worth $135K in total on Oct 1, 2026. Shares held after the trade: 1,328,130 (-2.2%).
AMG BBH Asset-Backed Credit Fund Insider Neil Martin Hohmann Buys $90K of Stock
Neil Martin Hohmann bought 9,020 shares of AMG BBH Asset-Backed Credit Fund, LLC at $9.98 a share, worth $90K in total on Jul 1, 2026. Shares held after the trade: 4,510.